Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) just unveiled an announcement.
PolyNovo Limited is poised to benefit from proposed changes to U.S. Medicare reimbursement for outpatient wound care, which aim to create a more value-oriented market by implementing a flat reimbursement rate. This change could enhance the competitiveness of PolyNovo’s cost-effective products, sustain their profit margins, and open significant growth opportunities in the outpatient sector, particularly as physicians focus more on clinical outcomes.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.30 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive ASX 200 medical technology company based in Melbourne, Australia. The company focuses on simplifying the management of acute complex wounds, offering products that redefine healing with significantly differentiated patient outcomes across various wound types. With a track record of treating over 70,000 patients in 46 countries, PolyNovo is actively investing in growth through new products, indications, and market expansions.
Average Trading Volume: 2,428,287
Technical Sentiment Signal: Sell
Current Market Cap: A$908.5M
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.